TPG-backed firm to absorb Indian drugmaker’s contract development biz, go public

Premium

An Indian biopharmaceutical company that counts private equity firm TPG as an investor will absorb a local drugmaker’s contract development and manufacturing organisation (CDMO) and soft gelatin business and list on stock exchanges.  The multi-stage transaction will involve Stelis Biopharma Ltd, which secured $195 million from TPG Growth and other investors ......